Depends on the drug being used, obviously. He talked about doing the math on relative brain penetration and ensuring that dosing frequency maintained sufficient blood levels.
Making sure the antiviral drug can enter the brain and making sure the drug levels in the blood/CSF are sufficiently high to suppress the virus are both
very important considerations for any antiviral treatment.
There are now many drugs and drug combinations to treat HIV. In order to help doctors decide which drug combinations are best at suppressing the virus, government guidelines have been produced, based on many epidemiological investigations, that recommend specific drug combinations to doctors treating patients. These guidelines have been used in the treatment decisions affecting hundreds of thousands of patients.
The problem is that the many epidemiological investigations that informed the government guidelines only considered drug levels in the blood, with no consideration given to drug levels in the brain. As a result, there has been increasing awareness of HIV-Associated Neurocognitive Disorder (HAND) in recent years. Some people note that HAND occurs in patients with undetectable levels of HIV in the blood, and erroneously conclude that HAND must be an inevitable consequence of HIV infection.
The reality is that if you take into consideration the ability of drugs to penetrate the brain, you can come up with new guidelines that suggest drug combinations that can suppress the virus in the brain as well as in the blood. But, as far as I know, no one is pushing for this to happen.
In the case of anti-herpesvirus drugs, there are sometimes those in the ME community who advocate for "low-dose" treatment strategies, where the level of drug in the blood is insufficient to suppress the virus. Although many supplements and drugs have a linear dose-response relationship that allows for a "start low and go slow" approach, direct-acting antivirals (DAAs) do NOT have a linear dose-response relationship, and low-dose therapy can often lead to evolution of drug resistant mutations in the virus.
Related discussion:
https://forums.phoenixrising.me/threads/drs-who-treat-with-low-dose-valcyte.39092/#post-625819